Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Papillary Renal Cell Carcinomas Rewire Glutathione Metabolism and Are Deficient in Both Anabolic Glucose Synthesis and Oxidative Phosphorylation.

Al Ahmad A, Paffrath V, Clima R, Busch JF, Rabien A, Kilic E, Villegas S, Timmermann B, Attimonelli M, Jung K, Meierhofer D.

Cancers (Basel). 2019 Sep 3;11(9). pii: E1298. doi: 10.3390/cancers11091298.

2.

VEGF - Supplemented extracellular matrix is sufficient to induce endothelial differentiation of human iPSC.

Ullah I, Abu-Dawud R, Busch JF, Rabien A, Erguen B, Fischer I, Reinke P, Kurtz A.

Biomaterials. 2019 Sep;216:119283. doi: 10.1016/j.biomaterials.2019.119283. Epub 2019 Jun 18.

3.

Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear-Cell and Papillary Renal-Cell Carcinoma.

Müller T, Tolkach Y, Stahl D, Steiner S, Hauser S, Ellinger J, Rabien A, Ralla B, Jung K, Stephan C, Kristiansen G.

Clin Genitourin Cancer. 2019 Feb;17(1):e167-e175. doi: 10.1016/j.clgc.2018.10.008. Epub 2018 Oct 23.

PMID:
30448104
4.

Diagnostic and Prognostic Potential of MicroRNA Maturation Regulators Drosha, AGO1 and AGO2 in Urothelial Carcinomas of the Bladder.

Rabien A, Ratert N, Högner A, Erbersdobler A, Jung K, Ecke TH, Kilic E.

Int J Mol Sci. 2018 May 31;19(6). pii: E1622. doi: 10.3390/ijms19061622.

5.

Circular RNAs: a new class of biomarkers as a rising interest in laboratory medicine.

Franz A, Rabien A, Stephan C, Ralla B, Fuchs S, Jung K, Fendler A.

Clin Chem Lab Med. 2018 Nov 27;56(12):1992-2003. doi: 10.1515/cclm-2018-0231.

6.

Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role.

Spatz S, Tolkach Y, Jung K, Stephan C, Busch J, Ralla B, Rabien A, Feldmann G, Brossart P, Bundschuh RA, Ahmadzadehfar H, Essler M, Toma M, Müller SC, Ellinger J, Hauser S, Kristiansen G.

J Urol. 2018 Feb;199(2):370-377. doi: 10.1016/j.juro.2017.08.079. Epub 2017 Aug 19.

PMID:
28827104
7.

Punicalagin, a polyphenol from pomegranate fruit, induces growth inhibition and apoptosis in human PC-3 and LNCaP cells.

Adaramoye O, Erguen B, Nitzsche B, Höpfner M, Jung K, Rabien A.

Chem Biol Interact. 2017 Aug 25;274:100-106. doi: 10.1016/j.cbi.2017.07.009. Epub 2017 Jul 11.

PMID:
28709945
8.

Antioxidant and antiproliferative potentials of methanol extract of Xylopia aethiopica (Dunal) A. Rich in PC-3 and LNCaP cells.

Adaramoye OA, Erguen B, Nitzsche B, Höpfner M, Jung K, Rabien A.

J Basic Clin Physiol Pharmacol. 2017 Jul 26;28(4):403-412. doi: 10.1515/jbcpp-2016-0156.

PMID:
28599387
9.

Epithelial-mesenchymal transition-associated microRNA/mRNA signature is linked to metastasis and prognosis in clear-cell renal cell carcinoma.

Mlcochova H, Machackova T, Rabien A, Radova L, Fabian P, Iliev R, Slaba K, Poprach A, Kilic E, Stanik M, Redova-Lojova M, Svoboda M, Dolezel J, Vyzula R, Jung K, Slaby O.

Sci Rep. 2016 Aug 23;6:31852. doi: 10.1038/srep31852.

10.

Cooperative Effect of miR-141-3p and miR-145-5p in the Regulation of Targets in Clear Cell Renal Cell Carcinoma.

Liep J, Kilic E, Meyer HA, Busch J, Jung K, Rabien A.

PLoS One. 2016 Jun 23;11(6):e0157801. doi: 10.1371/journal.pone.0157801. eCollection 2016.

11.

PI3K/AKT Signaling Pathway Is Essential for Survival of Induced Pluripotent Stem Cells.

Hossini AM, Quast AS, Plötz M, Grauel K, Exner T, Küchler J, Stachelscheid H, Eberle J, Rabien A, Makrantonaki E, Zouboulis CC.

PLoS One. 2016 May 3;11(5):e0154770. doi: 10.1371/journal.pone.0154770. eCollection 2016.

12.

Tissue Microdissection.

Rabien A, Kristiansen G.

Methods Mol Biol. 2016;1381:39-52. doi: 10.1007/978-1-4939-3204-7_2.

PMID:
26667453
13.

Antioxidant, antiangiogenic and antiproliferative activities of root methanol extract of Calliandra portoricensis in human prostate cancer cells.

Adaramoye O, Erguen B, Oyebode O, Nitzsche B, Höpfner M, Jung K, Rabien A.

J Integr Med. 2015 May;13(3):185-93. doi: 10.1016/S2095-4964(15)60175-3.

PMID:
26006031
14.

A Grainyhead-Like 2/Ovo-Like 2 Pathway Regulates Renal Epithelial Barrier Function and Lumen Expansion.

Aue A, Hinze C, Walentin K, Ruffert J, Yurtdas Y, Werth M, Chen W, Rabien A, Kilic E, Schulzke JD, Schumann M, Schmidt-Ott KM.

J Am Soc Nephrol. 2015 Nov;26(11):2704-15. doi: 10.1681/ASN.2014080759. Epub 2015 Mar 18.

15.

Renal cell neoplasias: reversion-inducing cysteine-rich protein with Kazal motifs discriminates tumor subtypes, while extracellular matrix metalloproteinase inducer indicates prognosis.

Rabien A, Stephan C, Kilic E, Weichert W, Kristiansen G, Miller K, Jung K, Erbersdobler A.

J Transl Med. 2013 Oct 16;11:258. doi: 10.1186/1479-5876-11-258.

16.

Deregulation of the COP9 signalosome-cullin-RING ubiquitin-ligase pathway: mechanisms and roles in urological cancers.

Gummlich L, Rabien A, Jung K, Dubiel W.

Int J Biochem Cell Biol. 2013 Jul;45(7):1327-37. doi: 10.1016/j.biocel.2013.03.023. Epub 2013 Apr 10. Review.

PMID:
23583660
17.

High extracellular matrix metalloproteinase inducer/CD147 expression is strongly and independently associated with poor prognosis in colorectal cancer.

Stenzinger A, Wittschieber D, von Winterfeld M, Goeppert B, Kamphues C, Weichert W, Dietel M, Rabien A, Klauschen F.

Hum Pathol. 2012 Sep;43(9):1471-81. doi: 10.1016/j.humpath.2011.10.023. Epub 2012 Mar 12.

PMID:
22417846
18.

Feedback networks between microRNAs and epigenetic modifications in urological tumors.

Liep J, Rabien A, Jung K.

Epigenetics. 2012 Apr;7(4):315-25. doi: 10.4161/epi.19464. Epub 2012 Apr 1. Review.

PMID:
22414795
19.

Reversion-inducing cysteine-rich protein with Kazal motif (RECK) expression: an independent prognostic marker of survival in colorectal cancer.

Stenzinger A, von Winterfeld M, Rabien A, Warth A, Kamphues C, Dietel M, Weichert W, Klauschen F, Wittschieber D.

Hum Pathol. 2012 Aug;43(8):1314-21. doi: 10.1016/j.humpath.2011.10.012. Epub 2012 Mar 6.

PMID:
22397871
20.

Tumor suppressor p16INK4a controls oncogenic K-Ras function in human pancreatic cancer cells.

Rabien A, Sanchez-Ruderisch H, Schulz P, Otto N, Wimmel A, Wiedenmann B, Detjen KM.

Cancer Sci. 2012 Feb;103(2):169-75. doi: 10.1111/j.1349-7006.2011.02140.x. Epub 2011 Dec 15.

21.

RECK overexpression decreases invasive potential in prostate cancer cells.

Rabien A, Ergün B, Erbersdobler A, Jung K, Stephan C.

Prostate. 2012 Jun 15;72(9):948-54. doi: 10.1002/pros.21498. Epub 2011 Oct 24.

PMID:
22025325
22.

Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness.

Wittschieber D, Stenzinger A, Klauschen F, Stephan C, Jung K, Erbersdobler A, Rabien A.

Pathobiology. 2011;78(3):123-31. doi: 10.1159/000323563. Epub 2011 May 26.

23.

New 4-maleamic acid and 4-maleamide peptidyl chalcones as potential multitarget drugs for human prostate cancer.

Rodrigues J, Abramjuk C, Vásquez L, Gamboa N, Domínguez J, Nitzsche B, Höpfner M, Georgieva R, Bäumler H, Stephan C, Jung K, Lein M, Rabien A.

Pharm Res. 2011 Apr;28(4):907-19. doi: 10.1007/s11095-010-0347-8. Epub 2010 Dec 24.

PMID:
21184149
24.

Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature.

Jung K, Fleischhacker M, Rabien A.

Clin Chim Acta. 2010 Nov 11;411(21-22):1611-24. doi: 10.1016/j.cca.2010.07.032. Epub 2010 Aug 2. Review.

PMID:
20688053
25.

KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy.

Rabien A, Fritzsche FR, Jung M, Tölle A, Diamandis EP, Miller K, Jung K, Kristiansen G, Stephan C.

Int J Cancer. 2010 Nov 15;127(10):2386-94. doi: 10.1002/ijc.25435.

26.

Laser microdissection.

Rabien A.

Methods Mol Biol. 2010;576:39-47. doi: 10.1007/978-1-59745-545-9_3.

PMID:
19882256
27.

CD146 protein in prostate cancer: revisited with two different antibodies.

Fritzsche FR, Wassermann K, Rabien A, Schicktanz H, Dankof A, Loening SA, Dietel M, Jung K, Kristiansen G.

Pathology. 2008 Aug;40(5):457-64. doi: 10.1080/00313020802197996.

PMID:
18604730
28.

High expression of KLK14 in prostatic adenocarcinoma is associated with elevated risk of prostate-specific antigen relapse.

Rabien A, Fritzsche F, Jung M, Diamandis EP, Loening SA, Dietel M, Jung K, Stephan C, Kristiansen G.

Tumour Biol. 2008;29(1):1-8. doi: 10.1159/000132565. Epub 2008 May 23.

PMID:
18497543
29.

ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.

Fritzsche FR, Jung M, Tölle A, Wild P, Hartmann A, Wassermann K, Rabien A, Lein M, Dietel M, Pilarsky C, Calvano D, Grützmann R, Jung K, Kristiansen G.

Eur Urol. 2008 Nov;54(5):1097-106. Epub 2007 Nov 26.

PMID:
18061337
30.

[Tumor suppressor RECK in prostate carcinoma. Decreased RECK expression as indicator of proteolytic imbalance].

Rabien A, Jung M, Fritzsche F, Loening SA, Kristiansen G, Jung K.

Urologe A. 2007 Sep;46(9):1081-2. German. No abstract available.

PMID:
17628776
31.

[Quantifying gene expression in prostate carcinoma. Which endogenous reference genes are suitable?].

Jung M, Ohl F, Stephan C, Rabien A, Kristiansen G, Radonić A, Loening SA, Jung K.

Urologe A. 2007 Sep;46(9):1083-4. German. No abstract available.

PMID:
17628775
32.

[Human kallikreins as tumor markers. Validation of potential marker of prostate cancer in serum and tissue].

Rabien A, Kristiansen G, Diamandis EP, Jung K, Stephan C.

Urologe A. 2007 Sep;46(9):1070-1. German. No abstract available.

PMID:
17605120
33.

ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis.

Fritzsche FR, Jung M, Xu C, Rabien A, Schicktanz H, Stephan C, Dietel M, Jung K, Kristiansen G.

Virchows Arch. 2006 Dec;449(6):628-36. Epub 2006 Nov 8.

PMID:
17106710
34.

Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.

Rabien A, Burkhardt M, Jung M, Fritzsche F, Ringsdorf M, Schicktanz H, Loening SA, Kristiansen G, Jung K.

Eur Urol. 2007 May;51(5):1259-66. Epub 2006 Jun 14.

PMID:
16806661
35.

Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization?

Ohl F, Jung M, Xu C, Stephan C, Rabien A, Burkhardt M, Nitsche A, Kristiansen G, Loening SA, Radonić A, Jung K.

J Mol Med (Berl). 2005 Dec;83(12):1014-24. Epub 2005 Oct 7.

PMID:
16211407
36.
37.

Interferon-gamma inhibits growth of human neuroendocrine carcinoma cells via induction of apoptosis.

Detjen KM, Kehrberger JP, Drost A, Rabien A, Welzel M, Wiedenmann B, Rosewicz S.

Int J Oncol. 2002 Nov;21(5):1133-40.

PMID:
12370765

Supplemental Content

Loading ...
Support Center